Jazz Pharmaceuticals Plc Financials

JAZZ

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Jazz Pharmaceuticals Plc (JAZZ) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 74/100

Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Jazz Pharmaceuticals Plc has an operating margin of 17.6%, meaning the company retains $18 of operating profit per $100 of revenue. This strong profitability earns a score of 88/100, reflecting efficient cost management and pricing power. This is up from 15.1% the prior year.

Growth

Jazz Pharmaceuticals Plc's revenue grew 6.1% year-over-year to $4.1B, a solid pace of expansion. This earns a growth score of 46/100.

Leverage

Jazz Pharmaceuticals Plc has a moderate D/E ratio of 1.48. This balance of debt and equity financing earns a leverage score of 56/100.

Liquidity

100

With a current ratio of 4.46, Jazz Pharmaceuticals Plc holds $4.46 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

100

Jazz Pharmaceuticals Plc converts 33.4% of revenue into free cash flow ($1.4B). This strong cash generation earns a score of 100/100.

Returns

Jazz Pharmaceuticals Plc's ROE of 13.7% shows moderate profitability relative to equity, earning a score of 55/100. This is up from 11.1% the prior year.

Altman Z-Score Distress

1.79

Jazz Pharmaceuticals Plc scores 1.79, below the 1.81 distress threshold. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Piotroski F-Score Strong

7/9

Jazz Pharmaceuticals Plc passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

2.49x

For every $1 of reported earnings, Jazz Pharmaceuticals Plc generates $2.49 in operating cash flow ($1.4B OCF vs $560.1M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Revenue

$4.1B

YoY+6.1%

5Y CAGR+13.5%

10Y CAGR+13.2%

Jazz Pharmaceuticals Plc generated $4.1B in revenue in fiscal year 2024. This represents an increase of 6.1% from the prior year.

EBITDA

$749.4M

YoY+23.1%

5Y CAGR+6.5%

10Y CAGR+8.6%

Jazz Pharmaceuticals Plc's EBITDA was $749.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 23.1% from the prior year.

Free Cash Flow

$1.4B

YoY+27.1%

5Y CAGR+13.0%

10Y CAGR+13.8%

Jazz Pharmaceuticals Plc generated $1.4B in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 27.1% from the prior year.

Net Income

$560.1M

YoY+35.0%

5Y CAGR+1.4%

10Y CAGR+25.4%

Jazz Pharmaceuticals Plc reported $560.1M in net income in fiscal year 2024. This represents an increase of 35.0% from the prior year.

EPS (Diluted)

$8.65

YoY+41.8%

5Y CAGR-1.0%

10Y CAGR+25.0%

Jazz Pharmaceuticals Plc earned $8.65 per diluted share (EPS) in fiscal year 2024. This represents an increase of 41.8% from the prior year.

Cash & Debt

$2.4B

YoY+60.2%

5Y CAGR+30.5%

10Y CAGR+13.4%

Jazz Pharmaceuticals Plc held $2.4B in cash against $6.1B in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

61M

YoY-2.6%

5Y CAGR+1.6%

10Y CAGR-0.0%

Jazz Pharmaceuticals Plc had 61M shares outstanding in fiscal year 2024. This represents a decrease of 2.6% from the prior year.

Gross Margin

N/A

Operating Margin

17.6%

YoY+2.5pp

5Y CAGR-7.0pp

10Y CAGR+0.9pp

Jazz Pharmaceuticals Plc's operating margin was 17.6% in fiscal year 2024, reflecting core business profitability. This is up 2.5 percentage points from the prior year.

Net Margin

13.8%

YoY+2.9pp

5Y CAGR-10.4pp

10Y CAGR+8.8pp

Jazz Pharmaceuticals Plc's net profit margin was 13.8% in fiscal year 2024, showing the share of revenue converted to profit. This is up 2.9 percentage points from the prior year.

Return on Equity

13.7%

YoY+2.6pp

5Y CAGR-3.1pp

10Y CAGR+9.4pp

Jazz Pharmaceuticals Plc's ROE was 13.7% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 2.6 percentage points from the prior year.

R&D Spending

$884.0M

YoY+4.0%

5Y CAGR+24.1%

10Y CAGR+26.4%

Jazz Pharmaceuticals Plc invested $884.0M in research and development in fiscal year 2024. This represents an increase of 4.0% from the prior year.

Share Buybacks

$311.4M

YoY+15.4%

5Y CAGR+0.7%

10Y CAGR+22.1%

Jazz Pharmaceuticals Plc spent $311.4M on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents an increase of 15.4% from the prior year.

Capital Expenditures

$38.1M

YoY+58.9%

5Y CAGR-1.1%

10Y CAGR+0.5%

Jazz Pharmaceuticals Plc invested $38.1M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 58.9% from the prior year.

JAZZ Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$4.1B+6.1%	$3.8B+4.8%	$3.7B+18.3%	$3.1B+30.9%	$2.4B+9.3%	$2.2B
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$884.0M+4.0%	$849.7M+43.9%	$590.5M+16.7%	$505.7M+50.8%	$335.4M+11.9%	$299.7M
SG&A Expenses	$1.4B+3.1%	$1.3B-5.2%	$1.4B-2.4%	$1.5B+69.9%	$854.2M+15.9%	$736.9M
Operating Income	$716.6M+23.9%	$578.6M+983.0%	-$65.5M-138.5%	$170.3M-55.0%	$378.1M-29.0%	$532.4M
Interest Expense	N/A	$32.8M0.0%	$32.8M-63.5%	$89.9M+2.6%	$87.6M+40.2%	$62.5M
Income Tax	-$91.4M+23.8%	-$119.9M+24.4%	-$158.6M-173.4%	$216.1M+544.8%	$33.5M+145.8%	-$73.2M
Net Income	$560.1M+35.0%	$414.8M+285.1%	-$224.1M+32.0%	-$329.7M-238.2%	$238.6M-54.4%	$523.4M
EPS (Diluted)	$8.65+41.8%	$6.10+270.4%	$-3.58+35.1%	$-5.52-230.8%	$4.22-53.6%	$9.09

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	$1.1B+7.7%	$1.0B+16.5%	$897.8M-17.5%	$1.1B+6.3%	$1.0B+13.5%	$902.0M-10.9%	$1.0B+4.1%	$972.1M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$198.2M+4.3%	$190.0M+5.2%	$180.7M-24.9%	$240.5M+9.0%	$220.7M-0.9%	$222.8M+2.9%	$216.6M-7.6%	$234.4M
SG&A Expenses	$530.6M+48.1%	$358.4M-30.3%	$514.0M+39.2%	$369.3M+9.1%	$338.5M-3.7%	$351.7M-11.2%	$396.0M+28.5%	$308.3M
Operating Income	$57.5M+108.4%	-$686.4M-1128.1%	-$55.9M-129.3%	$190.8M-4.3%	$199.4M+201.2%	$66.2M-46.0%	$122.5M-28.9%	$172.4M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	-$242.4M-1311.9%	-$17.2M+3.6%	-$17.8M+69.2%	-$57.9M-88.9%	-$30.7M-362.7%	$11.7M+135.3%	-$33.1M+29.9%	-$47.2M
Net Income	$251.4M+135.0%	-$718.5M-676.4%	-$92.5M-148.4%	$191.1M+13.4%	$168.6M+1253.2%	-$14.6M-115.5%	$94.2M-35.9%	$146.8M
EPS (Diluted)	$4.08+134.8%	$-11.74-672.4%	$-1.52-151.2%	$2.97+19.3%	$2.49+1182.6%	$-0.23-116.4%	$1.40-34.6%	$2.14

JAZZ Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$12.0B+5.4%	$11.4B+5.2%	$10.8B-11.9%	$12.3B+88.2%	$6.5B+18.0%	$5.5B
Current Assets	$4.6B+34.7%	$3.4B+31.8%	$2.6B-0.2%	$2.6B-8.0%	$2.8B+74.2%	$1.6B
Cash & Equivalents	$2.4B+60.2%	$1.5B+70.9%	$881.5M+49.0%	$591.4M-44.1%	$1.1B+66.0%	$637.3M
Inventory	$480.4M-19.5%	$597.0M-16.4%	$714.1M-33.4%	$1.1B+1024.5%	$95.4M+21.4%	$78.6M
Accounts Receivable	$716.8M+1.6%	$705.8M+8.3%	$651.5M+15.6%	$563.4M+42.1%	$396.5M+11.4%	$356.0M
Goodwill	$1.7B-2.1%	$1.8B+3.6%	$1.7B-7.4%	$1.8B+90.7%	$958.3M+4.2%	$920.0M
Total Liabilities	$7.9B+3.4%	$7.7B-1.2%	$7.7B-7.0%	$8.3B+189.7%	$2.9B+18.5%	$2.4B
Current Liabilities	$1.0B-32.4%	$1.5B+64.7%	$933.2M+15.3%	$809.3M+23.8%	$653.7M+79.4%	$364.5M
Long-Term Debt	$6.1B+19.0%	$5.1B-10.3%	$5.7B-5.4%	$6.0B+225.6%	$1.8B+17.5%	$1.6B
Total Equity	$4.1B+9.5%	$3.7B+21.1%	$3.1B-22.2%	$4.0B+8.3%	$3.7B+17.6%	$3.1B
Retained Earnings	$1.1B+28.3%	$878.7M+19.8%	$733.6M-11.6%	$830.2M-28.4%	$1.2B+8.6%	$1.1B

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$11.4B+3.8%	$10.9B-5.1%	$11.5B-4.0%	$12.0B+5.7%	$11.4B+0.3%	$11.3B-0.6%	$11.4B+1.7%	$11.2B
Current Assets	$3.8B+12.1%	$3.4B-18.8%	$4.1B-10.8%	$4.6B+25.7%	$3.7B+4.0%	$3.5B+3.0%	$3.4B+5.8%	$3.2B
Cash & Equivalents	$1.3B+11.4%	$1.2B-36.1%	$1.9B-22.8%	$2.4B+78.0%	$1.4B-6.1%	$1.4B-4.2%	$1.5B+12.8%	$1.3B
Inventory	$483.1M-4.3%	$505.0M+2.5%	$492.8M+2.6%	$480.4M-11.4%	$542.6M-6.0%	$577.3M-3.3%	$597.0M-2.4%	$611.8M
Accounts Receivable	$764.4M+7.1%	$714.0M+9.3%	$653.0M-8.9%	$716.8M+2.7%	$698.0M-1.3%	$707.1M+0.2%	$705.8M+12.4%	$627.8M
Goodwill	$1.8B-0.9%	$1.8B+4.8%	$1.8B+2.5%	$1.7B-1.1%	$1.7B-0.2%	$1.7B-0.8%	$1.8B+2.8%	$1.7B
Total Liabilities	$7.4B+2.2%	$7.2B-1.7%	$7.4B-7.1%	$7.9B+4.2%	$7.6B-0.4%	$7.6B-0.3%	$7.7B-0.8%	$7.7B
Current Liabilities	$2.3B+9.8%	$2.1B+69.4%	$1.2B+17.7%	$1.0B-33.3%	$1.6B-0.4%	$1.6B+1.7%	$1.5B-2.3%	$1.6B
Long-Term Debt	$4.3B-0.1%	$4.3B-18.8%	$5.3B-12.2%	$6.1B+19.1%	$5.1B-0.1%	$5.1B-0.1%	$5.1B-0.1%	$5.1B
Total Equity	$4.0B+6.8%	$3.7B-11.2%	$4.2B+2.0%	$4.1B+8.8%	$3.8B+1.8%	$3.7B-1.1%	$3.7B+7.1%	$3.5B
Retained Earnings	$442.7M+131.4%	$191.3M-81.5%	$1.0B-8.2%	$1.1B+29.4%	$871.2M+0.8%	$864.0M-1.7%	$878.7M-0.6%	$884.3M

JAZZ Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	$1.4B+27.8%	$1.1B-14.1%	$1.3B+63.4%	$778.5M-13.5%	$899.6M+15.9%	$776.4M
Capital Expenditures	$38.1M+58.9%	$24.0M-17.5%	$29.0M+5.1%	$27.6M+84.2%	$15.0M-62.6%	$40.1M
Free Cash Flow	$1.4B+27.1%	$1.1B-14.1%	$1.2B+65.5%	$750.9M-15.1%	$884.6M+20.2%	$736.3M
Investing Cash Flow	-$508.2M-211.7%	-$163.1M+63.5%	-$446.2M+91.4%	-$5.2B-417.2%	-$1.0B-548.9%	-$155.3M
Financing Cash Flow	$20.5M+106.7%	-$305.3M+42.3%	-$529.5M-113.3%	$4.0B+651.9%	$528.1M+279.8%	-$293.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$311.4M+15.4%	$269.8M+499457.4%	$54K	$0-100.0%	$146.5M-51.4%	$301.4M

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	$474.6M+434.1%	$88.9M-79.3%	$429.8M+7.8%	$398.6M+20.3%	$331.4M+24.0%	$267.2M+59.7%	$167.3M-45.5%	$307.2M
Capital Expenditures	$15.2M+17.0%	$13.0M-6.6%	$13.9M+4.5%	$13.3M+87.4%	$7.1M+2.7%	$6.9M-31.7%	$10.1M+135.0%	$4.3M
Free Cash Flow	$459.4M+505.4%	$75.9M-81.8%	$415.9M+7.9%	$385.3M+18.8%	$324.3M+24.6%	$260.3M+65.6%	$157.2M-48.1%	$302.9M
Investing Cash Flow	-$327.8M+48.9%	-$641.0M-279.5%	-$168.9M+12.6%	-$193.3M+24.8%	-$257.1M+5.4%	-$271.9M-367.1%	$101.8M+158.4%	-$174.3M
Financing Cash Flow	-$10.8M+91.3%	-$124.5M+84.7%	-$813.5M-9730.4%	-$8.3M+94.9%	-$161.1M-184.8%	-$56.6M+43.6%	-$100.3M-27.8%	-$78.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$0	N/A	N/A	$0	N/A	N/A	$99.8M+34.2%	$74.4M

JAZZ Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	17.6%+2.5pp	15.1%+16.9pp	-1.8%-7.3pp	5.5%-10.5pp	16.0%-8.6pp	24.6%
Net Margin	13.8%+2.9pp	10.8%+16.9pp	-6.1%+4.5pp	-10.7%-20.8pp	10.1%-14.1pp	24.2%
Return on Equity	13.7%+2.6pp	11.1%	N/A	N/A	6.5%-10.3pp	16.8%
Return on Assets	4.7%+1.0pp	3.6%+5.7pp	-2.1%+0.6pp	-2.7%-6.3pp	3.6%-5.8pp	9.4%
Current Ratio	4.46+2.2	2.24-0.6	2.79-0.4	3.23-1.1	4.34-0.1	4.47
Debt-to-Equity	1.48+0.1	1.37-0.5	1.85+0.3	1.52+1.0	0.510.0	0.51
FCF Margin	33.4%+5.5pp	27.9%-6.1pp	34.0%+9.7pp	24.3%-13.2pp	37.4%+3.4pp	34.1%

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	5.1%+70.8pp	-65.6%-59.4pp	-6.2%-23.8pp	17.5%-1.9pp	19.5%+12.1pp	7.3%-4.8pp	12.1%-5.6pp	17.7%
Net Margin	22.3%+91.0pp	-68.7%-58.4pp	-10.3%-27.9pp	17.6%+1.1pp	16.5%+18.1pp	-1.6%-10.9pp	9.3%-5.8pp	15.1%
Return on Equity	6.3%	N/A	N/A	4.7%+0.2pp	4.5%	N/A	2.5%-1.7pp	4.2%
Return on Assets	2.2%+8.8pp	-6.6%-5.8pp	-0.8%-2.4pp	1.6%+0.1pp	1.5%+1.6pp	-0.1%-1.0pp	0.8%-0.5pp	1.3%
Current Ratio	1.65+0.0	1.62-1.8	3.38-1.1	4.46+2.1	2.37+0.1	2.27+0.0	2.24+0.2	2.06
Debt-to-Equity	1.09-0.1	1.17-0.1	1.28-0.2	1.48+0.1	1.36-0.0	1.38+0.0	1.37-0.1	1.46
FCF Margin	40.8%+33.5pp	7.3%-39.1pp	46.3%+10.9pp	35.4%+3.7pp	31.7%+2.8pp	28.9%+13.3pp	15.5%-15.6pp	31.2%

Similar Companies

Blueprint Medicines Corp BPMC

$8.4B

Legend Biotech Corp LEGN

$3.2B

Verona Pharma VRNA

$9.2B

Bio-Techne Corp TECH

$9.4B

Corcept Therapeutics Inc CORT

$4.2B

Frequently Asked Questions

What is Jazz Pharmaceuticals Plc's annual revenue?

Jazz Pharmaceuticals Plc (JAZZ) reported $4.1B in total revenue for fiscal year 2024. This represents a 6.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Jazz Pharmaceuticals Plc's revenue growing?

Jazz Pharmaceuticals Plc (JAZZ) revenue grew by 6.1% year-over-year, from $3.8B to $4.1B in fiscal year 2024.

Is Jazz Pharmaceuticals Plc profitable?

Yes, Jazz Pharmaceuticals Plc (JAZZ) reported a net income of $560.1M in fiscal year 2024, with a net profit margin of 13.8%.

What is Jazz Pharmaceuticals Plc's earnings per share (EPS)?

Jazz Pharmaceuticals Plc (JAZZ) reported diluted earnings per share of $8.65 for fiscal year 2024. This represents a 41.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Jazz Pharmaceuticals Plc's EBITDA?

Jazz Pharmaceuticals Plc (JAZZ) had EBITDA of $749.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Jazz Pharmaceuticals Plc have?

As of fiscal year 2024, Jazz Pharmaceuticals Plc (JAZZ) had $2.4B in cash and equivalents against $6.1B in long-term debt.

What is Jazz Pharmaceuticals Plc's operating margin?

Jazz Pharmaceuticals Plc (JAZZ) had an operating margin of 17.6% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Jazz Pharmaceuticals Plc's net profit margin?

Jazz Pharmaceuticals Plc (JAZZ) had a net profit margin of 13.8% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Jazz Pharmaceuticals Plc's return on equity (ROE)?

Jazz Pharmaceuticals Plc (JAZZ) has a return on equity of 13.7% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Jazz Pharmaceuticals Plc's free cash flow?

Jazz Pharmaceuticals Plc (JAZZ) generated $1.4B in free cash flow during fiscal year 2024. This represents a 27.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Jazz Pharmaceuticals Plc's operating cash flow?

Jazz Pharmaceuticals Plc (JAZZ) generated $1.4B in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Jazz Pharmaceuticals Plc's total assets?

Jazz Pharmaceuticals Plc (JAZZ) had $12.0B in total assets as of fiscal year 2024, including both current and long-term assets.

What are Jazz Pharmaceuticals Plc's capital expenditures?

Jazz Pharmaceuticals Plc (JAZZ) invested $38.1M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Jazz Pharmaceuticals Plc spend on research and development?

Jazz Pharmaceuticals Plc (JAZZ) invested $884.0M in research and development during fiscal year 2024.

Does Jazz Pharmaceuticals Plc buy back shares?

Yes, Jazz Pharmaceuticals Plc (JAZZ) spent $311.4M on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.

How many shares does Jazz Pharmaceuticals Plc have outstanding?

Jazz Pharmaceuticals Plc (JAZZ) had 61M shares outstanding as of fiscal year 2024.

What is Jazz Pharmaceuticals Plc's current ratio?

Jazz Pharmaceuticals Plc (JAZZ) had a current ratio of 4.46 as of fiscal year 2024, which is generally considered healthy.

What is Jazz Pharmaceuticals Plc's debt-to-equity ratio?

Jazz Pharmaceuticals Plc (JAZZ) had a debt-to-equity ratio of 1.48 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Jazz Pharmaceuticals Plc's return on assets (ROA)?

Jazz Pharmaceuticals Plc (JAZZ) had a return on assets of 4.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Jazz Pharmaceuticals Plc's Altman Z-Score?

Jazz Pharmaceuticals Plc (JAZZ) has an Altman Z-Score of 1.79, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Jazz Pharmaceuticals Plc's Piotroski F-Score?

Jazz Pharmaceuticals Plc (JAZZ) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Jazz Pharmaceuticals Plc's earnings high quality?

Jazz Pharmaceuticals Plc (JAZZ) has an earnings quality ratio of 2.49x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Jazz Pharmaceuticals Plc?

Jazz Pharmaceuticals Plc (JAZZ) scores 74 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.